Dr. Rosenbaum is the Director of the Center for the Neuroscience of Psychedelics at the Massachusetts General Hospital Research Institute where he employs his knowledge of how psychedelics promote neuroplasticity to advance the treatment of psychiatric and other brain disorders. Renowned for his work with mood and anxiety disorders and the pharmacotherapy of these conditions, he also serves as the Stanley Cobb Professor of Psychiatry at Harvard Medical School and the Director of the Center for Anxiety and Traumatic Stress Disorders at Mass General. Dr. Rosenbaum has authored more than 400 original articles and reviews; written/edited 20 books; and serves on a dozen editorial boards of professional journals. For 20 years, he chaired the top-ranked Psychiatry Department at Mass General where he led a team of 600 clinicians, researchers, and 150 trainees. A respected researcher whose work has centered on longitudinal studies of children whose parents have been diagnosed with mood and anxiety disorders, Dr. Rosenbaum also served as chair of Mass General’s Executive Committee on Research.

Dr. Rosenbaum was a 2018 recipient of the prestigious Ellis Island Medal of Honor; the 2016 winner of the Joseph B. Martin Dean’s Leadership Award for the Advancement of Women Faculty and the winner of the 2011 Massachusetts Association of Mental Health Friend and Leader Award. Additionally, he earned the 2007 C. Charles Burlingame Award for lifetime achievement in psychiatric research and education by the Institute of Living in Hartford, Conn.

Dr. Rosenbaum has served as president and the chairman of the Board of the Anxiety and Depression Association of America and sat on the boards of trustees at Mass General as well as the Partners Healthcare System. He is affiliated with the American Foundation for Suicide Prevention, serving as its immediate past president and as a member of its Board of Directors. He also serves as a co-Chair of Development at Mass General. Dr. Rosenbaum is a co-founder of Psy Therapeutics, which is dedicated to the discovery and development of novel therapeutics for brain disorders; and Sensorium Therapeutics, which works to identify novel therapeutics for psychiatric disorders from plant-derived lead molecular entities.

Dr. Rosenbaum received his undergraduate degree from Yale College and his medical degree from Yale School of Medicine. He completed his residency and fellowship in Psychiatry at Mass General, Harvard Medical School.